OUR NEW PROFILE IS: (NASDAQ: BTCY)
Biotricity is ringing the opening bell at the NASDAQ today.
BTCY has shown triple-digit, quarter-over-quarter, year-over-year growth since day 1.
Biotricity Reported Record Quarterly and Annual Revenue for Fiscal 2021
BTCY has been rated by Maxim Group, Noble Financial, and Northland Securities in the past 90 days, with price targets of $6 & $7
We wanted to update you regarding one of our recent profiles.
We showed you this company last month as a company we should be looking at over the long term.
Turn your attention back to Nasdaq: BTCY.
BTCY was on the OTC just two months ago. It has recently completed it’s up-listing to the Nasdaq, an accomplishment that many talk about and very few are actually able to execute on.
In fact, they are ringing the opening bell today and countless eyes will be on this one that might not have otherwise had the opportunity to take a look at what we feel has the potential to be extremely successful based on the tremendous year over year growth.
Remote Medical Diagnostic Company, Biotricity, To Ring The Nasdaq Stock Market Opening Bell On Thursday, October 7th
Founder and CEO Waqaas Al Siddiq and Members of Biotricity Management Team to Attend Opening Bell Ceremony on Thursday, October 7, 2021 at 9:30am E.T.
REDWOOD CITY, CA / ACCESSWIRE / October 6, 2021 / Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced it will be ringing the Opening Bell on the Nasdaq Stock Market on Thursday, October 7, 2021 at 9:30am E.T. Founder and Chief Executive Officer Waqaas Al-Siddiq will attend the Opening Bell Ceremony alongside members of the Biotricity team.
Since August, Biotricity has completed a financing to support sales expansion while minimizing dilution and maximizing shareholder value, listed on the Nasdaq exchange, and unveiled the expansion of its telehealth product portfolio, which increases the company’s total addressable market with a standalone product that functions independently or in conjunction with its core offering.
The bell-ringing event can be viewed on the Nasdaq live stream: https://www.nasdaq.com/marketsite/bell-ringing-ceremony
A replay of the ceremony will be available at a later date on the Biotricity investor relations website .
There is no doubt that the Nasdaq listing will bring a lot of fresh eyes to the company.
BTCY is reforming the healthcare market as one of the fastest-growing companies in the med-tech sector. The company bridges the gap in remote cardiac monitoring, preventive and chronic care management by using the power of IoT (internet of things), wearables, and connected devices.
Not only does the company offer real-time, comprehensive monitoring and diagnostic services for cardiac-related healthcare and comorbidities, but its devices are also built with features that can dispatch emergency care services should any anomalies or arrhythmias occur when a device is worn.
The company has shown triple-digit, quarter-over-quarter, year-over-year growth since day 1. This incredible growth has led Biotricity to be self-sufficient and innovative as it grows. With an existing customer base, a well-respected footprint within the medical community and a high rate of retention, Biotricity might be well-positioned to be a major player in this exploding arena for years to come.
BTCY is Targeting a Growing and Underserved Market with the Bioflux.
The company’s first and primary solution, Bioflux, addresses the growing and underserved Mobile Cardiac Telemetry (MCT) market.
Bioflux is a high-precision, single-unit MCT device providing real-time monitoring and transmission of ECG information from ambulatory patients. This entire system is a complete solution for remote cardiac monitoring that merges seamlessly with physicians’ existing platforms and workflows to better detect, diagnose, and monitor.
For medical practitioners, this solution looks to be technologically superior and more financially attractive too. Clinicians designed the Bioflux online portal for clinicians. After all, the prime features of the product were built after speaking with numerous healthcare professionals and seeing what their most requested features were.
They track over 100 billion heartbeats a year, monitored in real-time by their certified cardiac technicians with unmatched reporting capabilities.
REDWOOD CITY, CA / ACCESSWIRE / August 16, 2021 /Biotricity, Inc.(OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, is pleased to provide financial results for its fiscal 2022 first quarter, which ended June 30, 2021. Full financial results will be posted on EDGAR later today. Biotricity’s Q1 results maintain a trend of both sequential and year over year (YoY) growth, with revenue once again setting a new quarterly record.
For Q1 Fiscal 2022, management is noting the following highlights:
- Q1 revenue of $1.76 million represented the 9th consecutive quarter of triple digit YoY growth
- Quarterly revenue increased 290% when comparing the first quarter of fiscal 2022 to the corresponding quarter of fiscal 2021, showing continued acceleration over the 227% growth in Q4/2021, 162% growth in Q3/2021, and 115% growth in Q2/2021
- Quarterly sequential revenue increased 49% compared to 19% posted in the prior quarter, a significant acceleration bolstered by consistent month-over-month sequential growth
- The Company nearly tripled sales with a smaller corresponding increase in Operating Expenses, which rose only 17% to $4.2 million for Q1 FY22 compared to $3.6 million in the prior year
“Continuous quarter over quarter revenue growth is a testament to our continued effort to expand our salesforce and footprint, stated Dr. Waqaas Al-Siddiq “Our Technology as a Service (TaaS) model and highly competitive solution is attracting an increasing number of cardiologists to the Biotricity brand. We are still waiting to receive approval from the FDA for our Biotres holter product, which will give us a major new product to sell to our existing customers.”
“Our operating expenses were only 7% higher than last year, despite a major ramp up in sales, which provides a good measure of the scalability of our business,” said Biotricity’s CFO, John Ayanoglou. “While our year-over-year growth is increasing, our sequential quarterly growth is even more encouraging, coming it just shy of 50% in this quarter. As we have discussed in recent quarters, with multiple new products on the horizon, R&D spending continues to be strategically high, coming in at nearly $590,000 for the quarter, a 39% increase over the prior year.”
Based on current trends, the Company is projecting continued revenue growth for fiscal 2022 and into fiscal 2023. As a reminder, Biotricity filed a 510(K) seeking FDA approval for its new Biotres holter product on December 31, 2020 and is prepared for a fast launch following that approval. Although the approval process has been slowed somewhat by the widely reported FDA backlog, the process is otherwise on track in terms of the steps required of the Company.
(sourced from MarketBeat)
WHAT IS BIOTRICITY’S CONSENSUS RATING AND PRICE TARGET?
According to the issued ratings of 3 analysts in the last year, the consensus rating for Biotricity stock is Buy based on the current 3 buy ratings for BTCY. The average twelve-month price target for Biotricity is $6.67 with a high price target of $7.00 and a low price target of $6.00. Learn more on BTCY’s analyst rating history
DO WALL STREET ANALYSTS LIKE BIOTRICITY MORE THAN ITS COMPETITORS?
Analysts like Biotricity stock more than the stock of other Medical companies. The consensus rating score for Biotricity is 3.00 while the average consensus rating score for medical companies is 2.73. Learn more on how BTCY compares to other companies
DO MARKETBEAT USERS LIKE BIOTRICITY MORE THAN ITS COMPETITORS?
MarketBeat users like Biotricity stock less than the stock of other Medical companies. 65.22% of MarketBeat users gave Biotricity an outperform vote while medical companies recieve an average of 67.17% outperform votes by MarketBeat users.
DOES BIOTRICITY’S STOCK PRICE HAVE MUCH UPSIDE?
According to analysts, Biotricity’s stock has a predicted upside of 110.97% based on their 12-month price targets.
WHAT ANALYSTS COVER BIOTRICITY?
Company Expects New Personal Medical Device Kit to be available to customer by early 2022
REDWOOD CITY, CA / ACCESSWIRE / September 14, 2021 /Biotricity Inc.(NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has developed a personal medical device kit, Biokit, a bundled home-use set comprised of a digital thermometer, a pulse oximeter, and a blood pressure cuff. All three devices are FDA cleared, wireless capable and integrate into the Biotricity ecosystem, a platform for interconnectivity. This is the next step in the evolution of the Bioflux solution, where other available tools are fully integrated to create a complete solution for remote cardiac monitoring.
You can see that BTCY has recently made a strong move in the past 6 months and now we are seeing activity pick up and interest start to come into this one as the recent up-listing to the Nasdaq will attract a whole new class of investors who wouldn’t take a look at this one while it was listed on the OTC.
Biotricity Reports Record Quarterly and Annual Revenue for Fiscal 2021
REDWOOD CITY, CA / ACCESSWIRE / June 15, 2021 / Biotricity, Inc.(OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, is pleased to provide unaudited, preliminary financial results for its fiscal 2021 fourth quarter and fiscal year, which ended March 31, 2021. Full financial results will be posted on EDGAR by June 31, 2021. Biotricity’s Q4 and annual results continued a trend of both sequential and year over year (YoY) revenue growth, with revenue setting a new quarterly record in the fiscal fourth quarter.
For fiscal 2021, management is noting the following highlights:
- Q4 revenue of $1.2 million represented the 8th consecutive quarter of triple digit YoY growth
- Quarterly revenue increased 227%, showing significant acceleration over the 162% increase posted in the prior quarter
- Quarterly sequential revenue increased 19%, bolstered by a long-term trend of month-over-month sequential growth
- Net loss attributable to common stockholders amounted to $16.2 million, or 43.1 cents per share
- Annual revenue reached $3.4 million, a 139% increase over fiscal 2020
“Our growth this quarter was even stronger than last quarter, which is exciting to see, as this is purely organic and the impact of our new products has not yet begun,” stated Waqaas Al-Siddiq, CEO of Biotricity. “We are in that sweet spot of our revenue cycle where we are posting strong monthly, quarterly and annual growth, with visibility out several years. As we enter a period of expected revenue acceleration, our model is proving to be highly predictable based on our consistent ability to win accounts throughout the U.S. We expect to easily beat Q4 revenue in our current quarter ending June 30, 2021 and are targeting triple digit revenue growth for fiscal 2022.”
“Our gross operating expenses grew at a slower pace than our revenue in Q4, and in net terms were significantly offset by the forgiveness of the Company’s PPP loan. This outcome is also reflective of what will happen as our business scales,” said Biotricity’s CFO, John Ayanoglou. “Similar to last quarter, we continue to have upfront costs related to expanding our sales force and putting new equipment into the field, so there is a delayed positive impact from those expenses that will be seen in the form of revenue in future quarters. With multiple new products on the horizon, R&D spending continues to be necessarily high, currently at 46% of revenue, but down from the 68% figure from last quarter. Based on our sales pipeline and high customer retention rate, we have high confidence in our sources of future revenue growth.”
Dr. Waqaas Al-Siddiq added, “In the second half of calendar 2021, we plan to have a potent combination of an expanding sales force and new product offerings, which will continue our growth rate. As a result, we expect to increase our revenue projections by year-end, depending on the timing of future product launches. Our technology as a service (TaaS) model and best in class product line are now time tested and brings us a clear advantage, as we continue to win in the marketplace against competitors. We made the decision to build both our technology and salesforce in-house, which took considerable time and effort, but has resulted in a faster adoption track than our peers at this stage of the growth cycle. Today, we have some of the newest, most advanced products in our addressable market, which will expand from $1 billion up to $3 billion as we enter the Holter space. With a planned listing to a national stock exchange on the horizon, provided that the Company meets applicable listing requirements, and some major milestones pending, we have never been more excited about our potential to gain a meaningful share of the cardiac market.”
Company Expects New Personal Medical Device Kit to be available to customer by early 2022
Underwritten Public Offering of Common Stock Resulted in Total Gross Proceeds of $16 Million
Company’s Momentum Continuing with Sales Growth, Recent Nasdaq listing and Successful Equity Raise
REDWOOD CITY, CA / ACCESSWIRE / August 26, 2021 / (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced the pricing of an underwritten public offering of 5,000,000…
REDWOOD CITY, CA / ACCESSWIRE / August 25, 2021 / (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it intends to offer shares of its common stock for…
REDWOOD CITY, CA / ACCESSWIRE / May 4, 2021 / , Inc. (OTCQB:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, is pleased to announce that it’s Biotres…
SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Waqaas Al-Siddiq, CEO of Biotricity Inc. (OTCQB: BTCY) (“the Company”), a modern medical technology company delivering…
REDWOOD CITY, CA / ACCESSWIRE / March 15, 2021 / (OTCQB:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, is pleased to announce that CEO Waqaas Al-Siddiq…
REDWOOD CITY, CA / ACCESSWIRE / February 11, 2021 / Inc. (OTCQB:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, is pleased to provide unaudited,…
Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will discuss the highlights of its financial results for the third quarter of…
Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it has completed a series of closings pursuant to which it sold an aggregate gross proceeds…
Bioheart comfortably and continuously monitors daily activities and provides advanced heart performance data in a user-friendly format
Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it made a 510(k) submission to the U.S. Food and Drug Administration (FDA), on December…
Dr. Waqaas Al-Siddiq, Phd
Chairman, CEO & Founder
Waqaas, the founder of Biotricity, is a serial entrepreneur, a former investment advisor and an expert in wireless communication technology. Academically, he was distinguished for his various innovative designs in digital, analog, embedded, and micro-electro-mechanical products. His work was published in various conferences such as IEEE and the National Communication Council.
Waqaas has held several high-level design positions in IBM, AMD, and Intel. His achievements have been numerous in both the technical and academic world. Coupled with this, Waqaas has vast experience in leading various groups through his board experience and executive roles within start-ups, mid-sized companies, and non-profits.
Waqaas has a dual Bachelor’s degree in Computer Engineering and Economics, a Master’s in Computer Engineering from Rochester Institute of Technology, and a Master’s in Business Administration from Henley Business School. He also holds a Doctorate in Business with a specialty in Transformative Innovations and Billion Dollar Markets.
Norman Betts, Phd
Independent Board Member
Norman sits on the Boards of Directors of the Bank of Canada, Tembec Inc., New Brunswick Power Corporation, 49 North Resources Inc., Adex Mining Inc., Tanzanian Royalty Exploration Inc. and the University of New Brunswick Pension Plan for Academic Employees.
Norman is an Associate Professor in the Faculty of Business Administration at the University of New Brunswick in Fredericton. He is accomplished in the field of accounting and finance, with a mix of academic, public, and private-sector experience. He is an expert in accounting regulations, and has extensive experience in audits, risk management, governance and oversight. He was a member of the New Brunswick Legislative Assembly from 1993 to 2003 and held three different cabinet posts, including Minister of Finance from 1999 to 2001. Prior to entering politics, Norman was Assistant Dean of the MBA Programme and an Associate Professor at the University of New Brunswick as well as a partner in the accounting firm Shannon, Betts & Buffett.
Norman received a PhD in Management with a concentration in accounting and finance from Queen’s University School of Business in 1992 and a Bachelor of Business Administration from the University of New Brunswick in 1978. He also holds a Fellow Chartered Accountant designation.
Independent Board Member
Dave has spent the past 22 years in a variety of positions in the medical device industry. He was appointed CEO of Sunshine Heart in October of 2009 and served as President and Chief Executive Officer through November 2015. Dave took Sunshine Heart Public on NASDAQ in 2012 and raised over $120M during his tenure. The Company achieved a number of clinical, regulatory and research and development milestones under his leadership. Prior to joining Sunshine Heart, he was President and CEO of Milksmart, Inc., a privately held company developing a unique stent-like agricultural technology that increases milking efficiencies, output and quality. From 2004-2008, Dave was Vice President of Global Marketing for Cardiac Surgery and Cardiology at St. Jude Medical, Inc. While at St. Jude, he developed the strategic pan for the newly formed interventional division, directed the launch of several new products and oversaw the acquisition and integration of Velocimed, a privately held company in the cardiovascular space.
From 1999-2004, Dave held executive management positions at privately held A-Med Systems, Inc., an emerging medical technology company that developed ventricular assist devices (pVADs) for acute heart failure. His roles included Vice President of Marketing and Sales, Chief Operating Officer and Chief Executive Officer. From 1995- 1999, Dave served as Product Manager for Angioplasty Balloons and Director of Intravascular Ultrasound at SCIMED Life Systems, a privately held company that was engaged in the development, manufacture and marketing of medical devices to treat cardiovascular disease. SCIMED was acquired by Boston Scientific Corporation and now operates as a subsidiary of Boston Scientific. Dave holds an M.B.A. in Marketing Management from Duquesne University and a B.S. in Commerce and Engineering from Drexel University.
Independent Board Member
Patricia has spent over 25 years in a variety of global sales and distribution positions in the medical device industry, focusing on the field of Electrophysiology. In 2015, she founded and is currently the Managing Director of PJM Medical Consultants, supporting medical device companies entering the international market with market entry and product commercialization strategies. From 2008 to 2015, Pat served as VP – International and General Manager for Atricure, Inc. She achieved significant sales, market development and clinical science milestones, while defining strategic plans and pursuing technology development and acquisitions. From 2001 to 2008, Pat worked with Stereotaxis, Inc. in numerous executive positions including Worldwide VP – Clinical Services and VP – International Sales and Marketing.
Prior to Stereotaxis, Pat worked with EP MedSystems as International Marketing Manager for defibrillation and diagnostic catheters. She began her career in the medical industry at Boston Scientific from 1992 to 1997 while serving in several positions, including Sales and International Product Manager for EPT. Pat has earned a Bachelor of Science Degree in Marketing from the University of Florida and a Bachelor of Science in Nursing degree from the University of North Florida.
Independent Board Member
Steve Salmon has expertise in business development transactions, market development, finance, technology, and capital market. His most recent experience was as a Venture Capitalist for Latterell Venture Partners, where he managed a number of portfolio companies. Prior to becoming a VC, Mr. Salmon was a founder of Ensure Medical and Integrated Vascular Systems, both of which were successfully exited through acquisition. He also served as the CEO of Revascular which was also acquired. Mr. Salmon brings to Biotricity his deep expertise in raising capital, facilitating growth, and driving long term value.
Chief Financial Officer
John has over 25 years of accounting, finance, and operations experience, having previously served as CFO of several public companies and a regulated financial institution. As CFO of Equitable Group, Mr. Ayanoglou raised over $130 million of regulatory capital in common, preferred, and debenture offerings over successive transactions, all during a period of extreme capital market turbulence, helping to successfully grow assets under administration from $6.1 billion to over $10 billion to facilitate Equitable Bank in becoming Canada’s ninth largest bank. He was also the CFO and Corporate Secretary of Xceed Mortgage Corporation, where he partnered with an entrepreneurial top team to grow the business through the successful implementation of warehouse financing lines and other securitization programs including public term securitizations of over $700 million.
John has extensive experience as a trusted business advisor working with management teams and boards on business acquisition and consolidation, risk mitigation and turnaround, to establish efficient, effective operations. He is a CA, CPA with a Bachelor of Commerce degree in Finance and Economics from the University of Toronto and his ICD.D designation from the Institute of Corporate Directors and the Rotman School of Business.
Chief Development Officer
Amir is a serial entrepreneur with over 20 years of experience in launching companies and producing innovative products, services, and solutions. Amir is sought after for his expertise in transforming R&D technologies into products based on market needs, commercializing products for volume production, and establishing global distribution channels across the world.
Prior to joining Biotricity, Amir served as CEO at AT Labs Inc., where his team pioneered the concept of wireless mobile thin clients to access secure enterprise applications through the cloud. The efficacy of the robust solutions resulted in customers from healthcare, government, enterprise, and retail sectors, most of which spanned thousands of locations across the United States. His experience in developing such novel technologies has put him at the forefront of companies that have grown in revenue from zero to over $160 million. In his own ventures, he has worked with many leading industrial and financial institutional funders including Jafo, Bay Partners, and JP Morgan with whom he has raised over $35 million.
Vice President, Engineering
Spencer is an expert in wireless communication and has worked with the United States Department of Defense. His academic career was highlighted by various innovative projects and designs. Spencer obtained his undergraduate degree while balancing a full-time job at Flightline Systems Ultra Electronics, a small defense contractor. His specialties are in the design and implementation of radio frequency, digital, analog, embedded software and PC software. Spencer also has experience in working with marketing, sales, and manufacturing teams in order to develop products for large-scale output. Spencer has a Bachelor’s degree in Computer Engineering from Rochester Institute of Technology.
Thomas C. Nelson
Nelson serves as the president of Share Our Strength, a national nonprofit that is ending childhood hunger in America. Prior to joining Share Our Strength in 2011, Nelson was chief operating officer for AARP, where he led the build-out of its state strategy in all 53 US states and territories. In addition to serving as an adjunct professor at Georgetown University’s McDonough School of Business, Nelson has a long history of service to civic organizations, including his current position on the board of directors of ProInspire. Other board positions include, the board of counselors for the Davis Gerontology School at the University of Southern California; the board of the Certified Financial Planner Board of Standards; and the board of Community Wealth Partners. Nelson holds a Ph.D. from the University of Southern California and an M.A. from Columbia University.
John Rother, JD
Mr. Rother is President and CEO of the National Coalition on Health Care, America’s oldest and most diverse group working to achieve comprehensive health system change. Prior to joining the Coalition in 2011, Rother worked at AARP for over 27 years as the Executive Vice President for Policy, Strategy, and International Affairs where he led the development of AARP’s policy positions and advocacy strategies. Under his leadership, AARP engaged in public policy research and analysis, public education, and advocacy on health and retirement issues at the federal, state and international levels. Rother wrote numerous articles and was a frequent speaker on health, retirement security, the federal budget, and the boomer generation.
Prior to that, Rother was Staff Director and Chief Counsel for the U.S. Senate Special Committee on Aging under the direction of Chairman John Heinz and served as Special Counsel for Labor and Health to U.S. Senator Jacob Javits. He has consistently been named as one of the most powerful people in Healthcare and in 2010 received the Robert Ball Award for Outstanding Achievements in Social Insurance from the National Academy of Social Insurance for “lifetime advocacy to strengthen Social Security and Medicare.”
Daniel Sands, MD, MPH
Dr. Sands is passionate about healthcare transformation, non-visit based care, collaboration in healthcare, and participatory medicine. He spent six years at Cisco, as chief medical informatics officer, where he provided both internal and external health IT leadership and helped key customers with business and clinical transformation using IT. Sands’ prior position was chief medical officer for Zix Corporation, a leader in secure e-mail and e-prescribing. Sands also spent 13 years at Beth Israel Deaconess Medical Center in Boston, where he developed and implemented numerous systems to improve clinical care delivery and patient engagement.
He has earned degrees from Brown University, Ohio State University and the Harvard School of Public Health, and trained at Boston City Hospital and Boston’s Beth Israel Hospital. Sands currently holds an academic appointment at Harvard Medical School and maintains a primary care practice in which he makes extensive use of health IT. He works as a consultant for a variety of innovative companies. Sands is the recipient of numerous health IT awards, has been elected to fellowship in both the American College of Physicians and the American College of Medical Informatics, and is a founder and co-chair of the board of the Society for Participatory Medicine. In 2009, he was recognized by HealthLeaders Magazine as one of “20 People Who Make Healthcare Better.”